359 related articles for article (PubMed ID: 31479282)
1. The safety of anti-interleukins monoclonal antibodies for the treatment of psoriasis.
D'Adamio S; Silvaggio D; Lombardo P; Bianchi L; Talamonti M; Galluzzo M
Expert Opin Drug Saf; 2019 Nov; 18(11):1031-1041. PubMed ID: 31479282
[No Abstract] [Full Text] [Related]
2. Safety of biologics in psoriasis.
Kamata M; Tada Y
J Dermatol; 2018 Mar; 45(3):279-286. PubMed ID: 29226369
[TBL] [Abstract][Full Text] [Related]
3. Guselkumab for the treatment of moderate-to-severe plaque psoriasis.
Yang EJ; Sanchez IM; Beck K; Sekhon S; Wu JJ; Bhutani T
Expert Rev Clin Pharmacol; 2018 Apr; 11(4):333-344. PubMed ID: 29478344
[TBL] [Abstract][Full Text] [Related]
4. Risankizumab for the treatment of psoriasis.
Gu C; Yang J
Expert Rev Clin Pharmacol; 2019 Sep; 12(9):851-857. PubMed ID: 31460804
[No Abstract] [Full Text] [Related]
5. Secukinumab for treating plaque psoriasis.
Rothstein B; Gottlieb A
Expert Opin Biol Ther; 2016; 16(1):119-28. PubMed ID: 26577956
[TBL] [Abstract][Full Text] [Related]
6. A safety evaluation of guselkumab for the treatment of psoriasis.
Galluzzo M; D'Adamio S; Campione E; Bianchi L; Talamonti M
Expert Opin Drug Saf; 2018 Jul; 17(7):741-751. PubMed ID: 29897790
[TBL] [Abstract][Full Text] [Related]
7. New biologics in psoriasis: an update on IL-23 and IL-17 inhibitors.
Dong J; Goldenberg G
Cutis; 2017 Feb; 99(2):123-127. PubMed ID: 28319618
[TBL] [Abstract][Full Text] [Related]
8. New interleukin-23 pathway inhibitors in dermatology: ustekinumab, briakinumab, and secukinumab.
Kurzeja M; Rudnicka L; Olszewska M
Am J Clin Dermatol; 2011 Apr; 12(2):113-25. PubMed ID: 21348542
[TBL] [Abstract][Full Text] [Related]
9. Antibodies in the Treatment of Psoriasis: IL-12/23 p40 and IL-17a.
Leonardi CL
Semin Cutan Med Surg; 2016 Jun; 35(4 Suppl 4):S74-7. PubMed ID: 27551698
[TBL] [Abstract][Full Text] [Related]
10. New and emerging biologic therapies for moderate-to-severe plaque psoriasis: mechanistic rationales and recent clinical data for IL-17 and IL-23 inhibitors.
Gaspari AA; Tyring S
Dermatol Ther; 2015; 28(4):179-93. PubMed ID: 26201310
[TBL] [Abstract][Full Text] [Related]
11. Biologics in the treatment of pustular psoriasis.
Wang WM; Jin HZ
Expert Opin Drug Saf; 2020 Aug; 19(8):969-980. PubMed ID: 32615817
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis.
Jeon C; Sekhon S; Yan D; Afifi L; Nakamura M; Bhutani T
Hum Vaccin Immunother; 2017 Oct; 13(10):2247-2259. PubMed ID: 28825875
[TBL] [Abstract][Full Text] [Related]
13. The role of IL 23 in the treatment of psoriasis.
Puig L
Expert Rev Clin Immunol; 2017 Jun; 13(6):525-534. PubMed ID: 28165883
[TBL] [Abstract][Full Text] [Related]
14. The safety of ustekinumab for the treatment of psoriatic arthritis.
López-Ferrer A; Laiz A; Puig L
Expert Opin Drug Saf; 2017 Jun; 16(6):733-742. PubMed ID: 28441904
[TBL] [Abstract][Full Text] [Related]
15. Anti-IL17 therapies for psoriasis.
Silfvast-Kaiser A; Paek SY; Menter A
Expert Opin Biol Ther; 2019 Jan; 19(1):45-54. PubMed ID: 30500317
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic drug evaluation of brodalumab for the treatment of psoriasis.
Galluzzo M; Talamonti M; D'adamio S; Bianchi L
Expert Opin Drug Metab Toxicol; 2017 Jun; 13(6):679-691. PubMed ID: 28460549
[TBL] [Abstract][Full Text] [Related]
17. Does p40-targeted therapy represent a significant evolution in the management of plaque psoriasis?
Griffiths CE; Girolomoni G
J Eur Acad Dermatol Venereol; 2012 Aug; 26 Suppl 5():2-8. PubMed ID: 22758911
[TBL] [Abstract][Full Text] [Related]
18. Biologic Therapy in Psoriasis (Part II): Efficacy and Safety of New Treatment Targeting IL23/IL-17 Pathways.
Molinelli E; Campanati A; Brisigotti V; Offidani A
Curr Pharm Biotechnol; 2017; 18(12):964-978. PubMed ID: 29299984
[TBL] [Abstract][Full Text] [Related]
19. Ustekinumab in psoriasis immunopathology with emphasis on the Th17-IL23 axis: a primer.
Quatresooz P; Hermanns-Lê T; Piérard GE; Humbert P; Delvenne P; Piérard-Franchimont C
J Biomed Biotechnol; 2012; 2012():147413. PubMed ID: 22754278
[TBL] [Abstract][Full Text] [Related]
20. Secukinumab (AIN-457) for the treatment of Psoriasis.
Jaleel T; Elmets C; Weinkle A; Kassira S; Elewski B
Expert Rev Clin Pharmacol; 2016; 9(2):187-202. PubMed ID: 26647300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
